12-5 | As negotiators from the 16 countries in the Regional Comprehensive Economic Partnership (RCEP) meet in Tangerang, Indonesia, starting today, Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines. With ratification and implementation of the highly controversial Trans-Pacific Partnership (TPP) trade agreement increasingly in doubt,
11-14 | Pfizer and GlaxoSmithKline (GSK) should extend their price reduction to all developing countries. Médecins Sans Frontières/Doctors Without Borders (MSF) welcomes Pfizer’s decision to lower the price of its pneumococcal conjugate vaccine (PCV) for children caught in humanitarian emergencies.
In lead-up to RCEP trade deal negotiations in China, MSF urges countries not to trade away access to medicines
10-11 | As negotiators for the Regional Comprehensive Economic Partnership (RCEP) trade agreement prepare to meet in Tianjin, China, from 16-22 October, Médecins Sans Frontières (MSF)/Doctors Without Borders urges the 16 negotiating countries to reject any terms in the deal that will harm access to medicines.
9-14 | As UN General Assembly starts, MSF urges governments to set medical research policies that align with people’s health needs New MSF report exposes pharma industry failings and highlights new ways of researching and developing medicines that address public health needs Governments must do more to promote the development of desperately-needed new medicines, vaccines, and diagnostics at affordable prices, urges Médecins Sans Frontières (MSF), in a new report.
MSF report shows price of older HIV drugs decreasing, but salvage regimens are 18 times more expensive than first-line treatment
7-21 | Trade agreements and pressure on India’s ‘pharmacy of the developing world’ pose major threats to access Médecins Sans Frontières (MSF) today released the 18th edition of its HIV drug pricing report, Untangling the Web of Antiretroviral Price Reductions, at the International AIDS Conference in Durban, South Africa. The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach.